If Vertex Has Such a Commanding Hold on the CFTR Modulator Market, Why Are Other Drug Makers Joining the Race?

With news of the emerging biotech company, Sionna, coming out of stealth yesterday, there is, once again, a reinvigorated hope for more transformational cystic fibrosis medicines on the horizon. In case you missed it, Sionna is attempting to correct CFTR with a small molecule drug like Vertex’s class of modulators but is targeting a different...
Continue reading...